ABL1 and acute lymphoblastic leukemia: Before the introduction of targeted BCR-ABL specific tyrosine kinase inhibitors (TKIs), Adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) were insufficiently sensitive to standard chemotherapy regimens, resulting in no improvement in overall survival (Faderl et al., 2009).